Pharma's Almanac TV
PA TV
Follow the Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
Regulatory
116 Articles Available
1
5
Can't find what you're looking for? Try our
advanced search
.
Fill-Finish Services
Avara Liscate: High Standards and Expertise in Sterile Manufacturing
PAP-Q2-20-CL-005
COVID-19
Regulating Clinical Trials in Pandemic Times
PAP-Q2-20-NI-005
Partnership
Yseop and Litera Partner to Fast-Track Regulation Submission Processes for Life Sciences Companies
PR-M01-20-NI-011
Glocalization
From Regulatory Convergence to Global Regulatory Harmonization
PAP-Q3-19-NI-004
Manufacturing Technology
Q: How does your company manage to provide local services/support while still efficiently managing global compliance?
PAP-Q2-19-NI-006
Novel Therapies
Q: What do you identify as the greatest advances that have been achieved in recent years with respect to harmonization of pharmaceutical regulations?
PAP-Q2-19-NI-007
Regulatory
Are EMA and FDA Decisions Diverging?
PAO-M08-19-NI-037
Fecal Transplant
Fecal Transplant Associated with One Patient Death
PAO-M06-19-NI-020
Regulatory
Regulatory Spotlight: Following the Tobacco Road
PAP-Q2-2019-NI-005
Regulatory Spotlight
Understanding the FDA’s Approach to Real-World Evidence
PAP-Q1-2019-NI-008
Opioids
Statement from FDA Commissioner Scott Gottlieb, M.D. on the Agency's 2019 policy and Regulatory Agenda for Continued Action to Forcefully Address Opioid Abuse
PR-M02-19-NI-061
Serialization
Regulatory Spotlight: FDA Delays Enforcement of Serialization Mandate
PAP-Q4-18-NI-011
FDA Approval
FDA Approves Expanded Use of Gardasil 9 to Include Individuals 27 Through 45 years old
PR-M10-18-NI-032
Regulatory
Competitive Generic Therapy: A New Patient-Centric FDA Pathway
PAP-Q3-18-NI-008
Regulatory
Meeting Regulatory Requirements: Rising to the Challenge with a Trusted Equipment Partner
PAP-Q3-18-CL-016
Drug Pricing
New Senate Bill Includes Amendment on Drug Pricing in Ads for Prescription Meds
PAO-M08-18-NI-026
Regulatory Approval
CERENOVUS Receives European Regulatory Approval For BRAVO Flow Diverter to Treat Intracranial Aneurysms
PR-M08-18-NI-088
Regulatory
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX® (daratumumab) Split Dosing Regimen
PR-M08-18-NI-093
Regulatory
China to Accelerate Review of 48 Foreign Drugs
PAO-M08-18-NI-013
China
Big Pharma Companies Taking New Drugs to China First
PAO-M08-18-NI-010
Regulatory
Reducing Time to Market with Targeted Regulatory Affairs Support
PAO-06-18-CL-003
Regulatory
Compliance at Hovione, Annual Inspection Review
PR-M03-18-NI-037
Regulatory
Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA
PR-M01-18-NI-060
Research
Medical Research Collaborating Center Selects Medidata to Meet Global Regulatory Requirements During Clinical Trials
PR-M01-18-NI-037
1
5
»
